Assembly Biosciences
ASMB
54 hedge funds and large institutions have $39.3M invested in Assembly Biosciences in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 17 closing their positions.
9,800% more call options, than puts
Call options by funds: $99K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.72% less ownership
Funds ownership: 4.02% → 3.3% (-0.72%)
13% less funds holding
Funds holding: 62 → 54 (-8)
27% less capital invested
Capital invested by funds: $53.8M → $39.3M (-$14.5M)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.84M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$264K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$243K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$242K |
| 5 |
Goldman Sachs
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.28M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.22M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.03M |
| 4 |
Renaissance Technologies
New York
|
-$957K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$946K |
ASMB Hedge Fund Activity: Q1 2022 in Review
54 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2022, worth a combined $39.3M — down 27% from $53.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ASMB and 9 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, adding an estimated $1.84M. The largest seller was Candriam SCA, exiting entirely with an estimated $4.28M sold.
- 54 institutional investors held Assembly Biosciences (ASMB) as of Q1 2022, down from 62 in Q4 2021.
- Funds reported $39.3M of Assembly Biosciences stock for Q1 2022, down 27% quarter-over-quarter.
- 9 funds opened new Assembly Biosciences positions in Q1 2022 and 17 closed out, a net change of -8 holders.
- The largest Assembly Biosciences buyer in Q1 2022 was Millennium Management, an estimated $1.84M added.
- The largest Assembly Biosciences seller in Q1 2022 was Candriam SCA, an estimated $4.28M sold.
Based on aggregated 13F filings for Q1 2022.